| abstract |
REFERRING TO A COMPOUND DERIVED FROM 1,2,4-TRIAZOLE AMINO FROM FORMULA I, WHERE X IS (a), (b), AMONG OTHERS, R1 IS METHYL, HALOGEN OR CYANE, R2 IS HO FLUORO, R3 AND R4 ARE EACH UNO C1-C3 ALKYL OR CYCLOPROPIL, R5 IS H, C1-C3 ALKYL OR CYCLOPROPIL, Z IS (c), (d), AMONG OTHERS, R6 AND R7 ARE EACH H, FLUORINE, C1-C3 ALKYL OR C1- ALCOXY C3. PREFERRED COMPOUNDS ARE: 5- {5 - [{[5- (3-CHLOROPHENYL) ISOXAZOL-3-IL] METHYL} (CYCLOPROPYL) AMINO] -4-METHYL-4H-1,2,4-TRIAZOL-3-IL } PYRIDAZIN-3 (2H) -ONE, 6- [4-ETHYL-5- (METHYL {[5- (3-METHYLPHENYL) ISOXAZOL-3-IL] METHYL} AMINO) -4H-1,2,4-TRIAZOLE -3-IL] PYRIMIDIN-4 (3H) -ONE; 2-METHYL-5- [4-METHYL-5- (METHYL {(1S) -1- [5- (3-METHYLPHENYL) ISOXAZOL-3-IL] ETHYL} AMINO) -4H-1,2,4-TRIAZOLE -3-IL] PYRIDAZIN-3 (2H) -ONE. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTORS mGLUR5, BEING USEFUL FOR THE TREATMENT OF SENILE DEMENTIA, PARKINSON'S DISEASE, SCHIZOPHRENIA, RETINOPATHIES, EPILEPSY, AMONG OTHERS |